Skip to main content
. 2013 Sep;4(3):264–284. doi: 10.3978/j.issn.2078-6891.2013.037

Table 2. Short term outcomes from randomised phase III studies integrating oxaliplatin as radiosensitizer.

Outcomes STAR-01 (Aschele 2011) (34)
ACCORD- 0405 (Gerard 2010) (38)
CAO/ARO/AIO-04 (Rodel 2012) (39)
NSABP R04 (Roh 2010) (40)
5-FU 379 OXA 352 Cape 293 OXA 291 5-FU 624 OXA 613 5-FU/cape 622 OXA 631
ypCR 16% 16% 14% 19% 13% 17% 19% 21%
Ypn+ 26% 29% 30% 28% 30% 28% Not stated Not stated
G3/G4 diarrhoea 4% 15% 3% 13% 8% 12% 7% 15%